Medical Cannabis Awareness Week 2026: a week that belongs to everyone | PatientsCann UK® Skip to content Awareness1 to 7 November 2026Community owned Medical Cannabis Awareness Week belongs to everyone Every year, from 1 to 7 November, patients, carers, families and supporters across the UK speak up about medical cannabis. No one owns the week. It is run by the community, for the community, and anyone can take part. PatientsCann UK®Awareness#MCAW #MCAW2026 Get involved this November On this page What is MCAW? A week for everyone The logo Why a week Our tours This year Get involved References At a glance When1 to 7 NovemberThe first week of November, every year. Why then1 November 2018The day medical cannabis became legal to prescribe in the UK. Who owns itNo oneIt is community owned and community run. Everyone is welcome. Join in#MCAW2026Share your story, host an event, or simply talk about it. Where it began What is Medical Cannabis Awareness Week? Medical Cannabis Awareness Week, often shortened to MCAW, is a yearly week of events, stories and conversations about cannabis as a medicine. It starts on 1 November. That date matters. On 1 November 2018, medical cannabis became legal to prescribe in the UK.2 The week was first started in 2020 by PLEA (Patient-Led Engagement for Access), a patient advocacy group.1,4 Patients shared their stories, doctors and advocates joined online panels, and people across the UK were asked to talk about medical cannabis with friends and family.1 In 2023, the week marked five years since medical cannabis became legal to prescribe, and ran from 1 to 7 November as it does every year.4 By then, PLEA had closed. The week could have faded away. Instead, the community picked it up and carried it on. Patients, volunteers and small groups kept the week alive, and PatientsCann UK® stepped in to help it grow. Community owned A week that belongs to everyone No person, company or group owns Medical Cannabis Awareness Week. It belongs to every patient who has ever had to explain their medicine. PatientsCann UK® MCAW has always been bigger than any one organisation. It grew because patients wanted it and because people gave their time for free. When the group that started it closed, the week did not close with it. That tells you who it really belongs to. Nobody needs permission to take part. You do not need to sign up to anyone, pay a fee or use a set logo. A patient talking to their GP, a family sharing a story online, a clinic holding an open day, a local group meeting in a cafe: all of these are Medical Cannabis Awareness Week. We think it should stay that way. PatientsCann UK® takes part every year, and we will keep doing so, but the week is not ours. It is yours. What MCAW is Community owned and community run. Free for anyone to join, share and take part in. Led by patients, their carers and their families. A shared moment, every 1 to 7 November. What MCAW is not Not owned by any person, company or organisation. Not something anyone needs permission to take part in. Not a brand or a product to sell. Not closed to anyone who wants to help. Free for everyone The MCAW logo, and yours These are the logos PatientsCann UK® uses for Medical Cannabis Awareness Week. We first used our logo in 2024, together with United Patients Alliance and the Medical Cannabis Patients Alliance (MCPA), a patient group that has since closed. We added two more for 2025. All of our logos are in the public domain. There is no copyright on them. Anyone can download them, print them, share them or change them, with no need to ask. After PLEA closed, the original MCAW logo was shared by patients, groups and businesses across the community. That logo has since been claimed under copyright. We do not think any symbol of this week should belong to one organisation, so ours are free for all. 2024 logoPublic domain. Free for anyone to use.Download 2025 logo, lightPublic domain. Free for anyone to use.Download 2025 logo, darkPublic domain. Free for anyone to use.Download Make your own. We would love to see how you picture Medical Cannabis Awareness Week. Design your own MCAW logo, share it on social media, tag PatientsCann UK® and use the hashtags: #MCAW#MCAW2026 Keeping it focused Why a week works better than a month Last year, some in the industry suggested a Medical Cannabis Awareness Month. It did not get off the ground, and we did not support it. A longer campaign sounds bigger, but it would take away the impact of the week. One loud moment. When everyone speaks up in the same seven days, the message is heard. Spread across a month, the same voices get lost. It fits patients. Many patients live with pain, fatigue or long-term illness. A week is something people can manage. A month is a lot to ask. It keeps the anniversary at the centre. The week starts on 1 November, the day medical cannabis became legal to prescribe. That link is part of what makes it meaningful. It stays about patients. A short, focused week keeps the attention on real people and real stories. What we have done On the road every November since 2023 PatientsCann UK® first took Medical Cannabis Awareness Week on the road in 2023, with a trial tour of Brighton, Hove and Exeter. Since 2024, we have followed a set route from Northern Ireland to London. We travel the whole of the UK, so that patients in every nation have a chance to meet us, ask questions and feel less alone. In 2024, the tour took patient advocates to Belfast, Glasgow, Birmingham, Cardiff and London.3,5 Where we can, we also join other events along the way. 1Northern IrelandWe start the week in Northern Ireland. 2ScotlandThen across the water to Scotland. 3The middle of EnglandDown to the heart of England. 4WalesOut

<p>The post Medical Cannabis Awareness Week first appeared on PatientsCann UK®.</p>

PatientsCann UK | Some Are More Equal Than Others Skip to content Equality law Prescription discrimination Opinion and analysis Some Are More Equal Than Others… Medical cannabis patients are often told that they are protected by the Equality Act 2010. For many patients, that may be true. But it is not true simply because somebody has been prescribed cannabis. PatientsCann UK® Equality Act 2010 and medical cannabis By Sal Aziz, Director On this page A prescription is not a disability certificate Who decides Presumed disabled? Volunteers Capacity matters Routes to discrimination Exceptions Finding common ground References Please note This article is general information about equality law and how PatientsCann UK® approaches it. It is not legal or medical advice. The legal test A prescription is not a disability certificate The Equality Act protects disability as a legal status. It does not create a separate protected characteristic of being a patient, taking prescribed medication or holding a medical cannabis prescription. It also does not apply universally to every relationship between an individual and an organisation. Protection depends both on whether the person meets the statutory definition of disability and on the capacity in which the organisation is dealing with them. That distinction creates an uncomfortable question: if the same practical accommodation can safely be offered to every lawful patient, why should compassion depend on whether the patient can prove that their condition crosses a legal threshold? Section 6 of the Equality Act defines disability as a physical or mental impairment having a substantial and long-term adverse effect on a person’s ability to carry out normal day-to-day activities. “Substantial” means more than minor or trivial, while “long-term” generally means that the effect has lasted, or is likely to last, at least 12 months or for the rest of the person’s life. Recurring conditions can also qualify. Some conditions receive special treatment. Cancer, HIV infection and multiple sclerosis are disabilities from diagnosis. Progressive conditions may qualify before their effects become substantial where the statutory test is satisfied. The Act also protects people who previously had a qualifying disability, subject to limited exceptions. Crucially for medical cannabis patients, the assessment normally considers what the impairment would be like without the measures being used to treat or correct it. Schedule 1 expressly includes medical treatment within those measures. A patient whose condition is well controlled by cannabis is therefore not necessarily excluded from protection simply because the treatment works. The relevant question may be what the condition would probably do without that treatment. Many medical cannabis patients are prescribed for serious, persistent or recurring conditions and are therefore likely to satisfy the definition. It would, however, be unsafe to claim that every patient is legally disabled. A prescription may provide important evidence of an underlying impairment and treatment, but it does not by itself establish the substantial, long-term effect required by section 6. The Equality Act’s exclusion of addiction to alcohol, nicotine or another substance should not be confused with lawful treatment using a controlled drug. The 2010 Disability Regulations exclude addiction itself as an impairment, subject to an exception where it originally resulted from medically prescribed drugs or other medical treatment. In most medical cannabis cases, the asserted disability will in any event be the underlying physical or mental impairment, not an assumed addiction to the prescribed medicine. Japan has arguably the most formalised and structured official framework in the world. The government issues physical booklets called Shōgaishatechō (障害者手帳) or Disability Handbook. Applications are generally made through the relevant local authority and supported by medical or specialist evidence. The precise assessment process depends on the type of certificate and the municipality involved. Pictured above is a Seishin Shōgaisha Hoken Fukushi Techō (精神障害者保健福祉手帳) or Mental Disability Health and Welfare Handbook. Similar schemes exist in other countries, such as Germany’s Schwerbehindertenausweis for severe disabilities. Whilst The Sunflower Scheme is available for anyone who self-identifies as having a hidden disability, and PIP is available for those with qualifying disability or long-term condition, no directly comparable scheme exists in the UK. 精神 手帳 京都市.jpg by Bitland is licensed under CC BY 4.0 Evidence and burden Who decides whether somebody is disabled? There is no universal Equality Act disability card and no general process through which every patient obtains a binding declaration before requesting fair treatment. Outside litigation, organisations and individuals must make practical decisions using the information reasonably available to them. Evidence might include a patient’s account of functional effects, prescription records and, where proportionate, relevant clinical or occupational-health evidence. If a dispute reaches legal proceedings, the court or tribunal ultimately determines whether the statutory definition was satisfied at the relevant time. Section 136 provides a shifting burden of proof in discrimination proceedings once there are facts from which a court could conclude, in the absence of another explanation, that a contravention occurred. That procedural rule does not make a prescription conclusive proof of disability, but neither does it entitle organisations to dismiss credible evidence until a patient has obtained a judgment. This leaves patients in a difficult position. They may have to disclose intimate medical information to establish rights that an organisation could have respected voluntarily from the outset. The more evidence demanded, the greater the intrusion. Yet if too little information is provided, an organisation may argue that it did not know, and could not reasonably have been expected to know, of the disability, particularly in a claim for discrimination arising from disability. Policy, not finding Should patients be presumed disabled in practice? As a strict statement of law, organisations should not declare every medical cannabis patient disabled. Not every patient will meet the definition, and disability is a status belonging to the person, not a label produced by the medicine. But there is an important difference between making a legal finding and adopting an inclusive policy. An organisation can usually choose to extend a proportionate adjustment, such as secure medicine storage, a private administration area, flexible breaks or an individual risk assessment, without first

<p>The post Some are more equal than others first appeared on PatientsCann UK®.</p>

PatientsCann UK | The Endocannabinoid System Visualizer Skip to content Science Interactive Peer reviewed sources The endocannabinoid system, explained by exploring your own body Every person reading this has an endocannabinoid system. It is a network of tiny switches, messengers and clean-up crews that keeps the body steady. Tap any part of the body below to see which switches sit there and what they do. PatientsCann UK Education, physiology Written for patients, carers and clinicians On this page The basics Body map How the signal works Makers and breakers What it balances Plant compounds Entourage effect Beyond CB1 and CB2 For clinicians Test yourself References What this page is, and is not This page teaches the science of how the body works. It is not medical advice and it does not recommend any product, dose or treatment. If you think medical cannabis might help you, speak to your GP, your specialist or a clinic on the General Medical Council register. Why this matters It is already yours The system is built into every human body from the first weeks in the womb. Cannabis did not put it there. It keeps you steady Sleep, appetite, pain, mood, movement, temperature and the immune response all get nudged back towards the middle. It is very old Versions of this system appear in animals going back around 450 million years, which is why it is found in so many species. It explains the effects Cannabis compounds work because they fit switches your body already has. Different switches, different effects. Start here Three parts, one job: keeping you steady Your body is a colony of billions of cells. Each cell has its own needs, and they all have to work together. To do that, cells send each other chemical messages. The endocannabinoid system, often shortened to ECS, is one of those messaging networks. Scientists often describe it as a lock and key. The receptor is the lock, sitting on the outside wall of a cell. The messenger molecule is the key. When the right key turns the right lock, something changes inside that cell. The three parts The locks (receptors). Two main ones, called CB1 and CB2. They sit on cell surfaces all over the body and each one changes what its cell does. The keys (endocannabinoids). Fatty messenger molecules your body builds itself. The two main ones are anandamide and 2-AG. The clean-up crew (enzymes). Tools that build the keys when they are needed and destroy them seconds later. The main destroyers are called FAAH and MAGL. The part that surprises people Most messaging systems keep a stock of messengers ready in tiny bags, waiting to be released. The ECS does not. Endocannabinoids are made on demand, cut fresh out of the fatty wall of the cell at the exact moment they are needed, used on the spot, and then broken down. Nothing is stored and nothing travels far. That is why the ECS is so precise. It does not act on the whole body at once. It acts in one small place, for a short time, only where something needs correcting. The word for it is homeostasis. It means keeping the inside of your body steady even when things outside change. Not too hot, not too cold. Not too much pain signal, not too little. The ECS is one of the body’s main tools for doing that. Where the plant comes in The keys your body makes fit the locks perfectly. Compounds from the cannabis plant, called phytocannabinoids, are shaped closely enough to fit the same locks, but they are not identical. Researchers sometimes call them a false key. They turn the lock, but not in quite the same way, not in the same place, and not for the same length of time. That single idea explains almost everything else on this page. Cannabis does not create new effects in the body. It leans on a control system that is already running. It is not the cannabis plant that has many effects, it is the endocannabinoid system that determines them. Dr Mariano Garcia de Palau, Fundacion CANNA Interactive body map Where the receptors are, and what they do there Tap a numbered marker on the body, or a name in the row underneath. CB1 markers are green, CB2 markers are purple, and places with a real mix of both are teal. Show Everything CB1 only CB2 only 13 regions to explore CB1 CB2 Both, in real numbers A note on the drawing. The illustration shows the main organs from the front. Each marker sits over the area that region covers, so a few point at parts that sit deeper in the body. The immune marker sits on a cluster of lymph nodes, and nerves and skin reach everywhere, so those markers show one place out of many. Step by step How one nerve cell tells another to calm down Nerve cells talk across a tiny gap called a synapse. Normally messages travel one way. The ECS is unusual: its message travels backwards. Step through it below. Presynaptic sending neuron Postsynaptic receiving neuron the synaptic gap vesicles CB1 receptor on the sending cell receptors glutamate or GABA Ca2+ up DAGL 2-AG cut from the cell wall backwards fewer messages sent MAGL broken down in seconds Back Next step Why the backwards direction matters. The cell that is getting too much noise is the one that turns the volume down, at the exact synapse where the noise is coming from. Nothing else in the body is affected. This is called retrograde signalling, and it is the reason cannabinoids can quieten over-firing nerves without shutting the whole nervous system down. The cast The makers, the messengers and the breakers Six molecules do most of the work. Two carry the message, two build them, two destroy them. Tap any name. The others, in brief Anandamide and 2-AG get the attention, but the body makes more: Noladin ether and virodhamine, both weaker relatives. Virodhamine may work against

<p>The post Endocannabinoid System first appeared on PatientsCann UK®.</p>

Skip to the explorer PatientsCann UK · Patient education From Seed to Patient: the UK medical cannabis pipeline Every legal prescription in the UK travels the same route: a controlled growing room, a licensed factory, an accredited laboratory, a border, a specialist clinic and a pharmacy. This explorer walks you through all six stages, compares the seven formats a patient can be prescribed, and shows you how to read the paperwork that proves it. 6 regulated stages 7 patient formats Quality and science inspector This is education, not medical advice. Onset and duration figures are typical ranges reported for each route. Your own response depends on your dose, your product and your body. Never change how you take your medicine without speaking to your prescriber or pharmacist. See all patient resources 1 The seed to shelf journey 2 Formats and delivery pathways 3 Quality and science inspector The six stages of a legal UK prescription Select any stage to open the detail. Each one has its own quality standard and its own regulator, and a batch cannot move forward until the stage before it has been signed off. 1Genetics and GACP growing 2GMP processing and extraction 3Laboratory testing and CoA 4Licensed import and border 5Specialist prescribing 6Pharmacy dispensing Stage 1 of 6 1 Genetics, breeding and GACP cultivation Where the medicine starts: a known plant, grown the same way every time. Standard GACPRegulator DEFRA and origin inspectors What happens here A licensed grower keeps a small number of mother plants and takes cuttings from them, often through tissue culture, so that every crop is genetically the same plant rather than a new cross. Growing rooms are closed loop: light, temperature, humidity, carbon dioxide and air filtering are all controlled and logged. Mother plant care and cutting or tissue culture cloning Batch to batch genetic stability, checked crop by crop Sealed rooms with filtered air and monitored water feeds Quality standard GACP (Good Agricultural and Collection Practice). It sets how the plant is grown, fed, harvested and handled. In practice it means no synthetic pesticides, and soil, water and fertiliser chosen so the plant does not draw heavy metals up into the flower. Where the flower is dispensed as it is, GACP alone is not enough: the maker has to write down the point at which production of the active substance begins, and for whole flower that point is the growing room. Who regulates it DEFRA in the UK, alongside the agricultural inspectors of the country the crop is grown in. Growers are inspected and have to keep records for every batch they release. One decision sets the whole rulebook What the crop is going to become decides where pharmaceutical rules start. It is the single most important point in the chain, and the one most often got wrong. If the flower itself is the medicine The plant is the active substance Propagation Cultivation and flowering Harvest, drying, curing Packed flower, dispensed as it is Annex 2, biological medicines Nothing downstream can purify or sterilise a dried bud, so quality has to be built in from the cuttings onward. Annex 2 recognises that manufacture can begin at propagation. If the flower will be extracted The plant is a starting material Propagation Cultivation and flowering Harvest and drying Extraction and formulation Annex 7, herbal starting materials Here quality is defined later. Extraction, filtering and purification can take impurities out, so the plant is grown under GACP and pharmaceutical rules begin at the processing step. Why sameness matters A prescription only works as medicine if the next jar behaves like the last one. Controlled genetics and controlled rooms are what let a pharmacist put a fixed cannabinoid percentage on a label. Illicit supply has none of this: the same street name can be a different plant, grown a different way, with a different strength every time, and nobody has tested it. Next: GMP processing 2 Pharmaceutical processing and GMP extraction The crop becomes a pharmaceutical product in a cleanroom. Standard EU and UK GMPRegulator MHRA What happens here Harvested flower is dried and cured at a set temperature and humidity, then milled to a controlled particle size for vaporising. For oils and cartridges the plant material goes through supercritical carbon dioxide extraction, then winterisation to strip out fats and waxes, with any solvent recovered and accounted for. Controlled drying, curing and precision milling Cold carbon dioxide extraction under pressure Winterisation, filtration and solvent recovery Standardising the extract to a fixed cannabinoid strength Quality standard EU and UK GMP (Good Manufacturing Practice). Work happens in cleanrooms with ISO class 5 and class 7 air handling and positive air pressure, so air always flows out of the clean space rather than into it. Every step is written down, signed and traceable to the batch. The rulebook is EudraLex Volume 4: Part I for finished medicines, Part II for active substances, and Annex 2 for medicinal cannabis intended for use as whole flower. Quality risk management sits across all of it. Who regulates it The MHRA, the UK medicines regulator. A site that makes or releases a medicine for UK patients has to hold and keep its GMP certification through inspection. Three routes out of the same growing room Where GACP stops and GMP starts depends on what the batch is going to become. Requirements tighten at every step closer to the patient. GACP, pre harvestGMP, post harvestGood distribution practice Bulk flower for extractionMother plantsRooting and hardeningLarge scale cultivationharvestFast fan assisted dryingMachine trimmingBulk packaging and shippingExtractionActive ingredientFormulationFilling and packaging Sold on as feedstock, so the later GMP steps happen at another site. Extracts, including oils, hash and rosinMother plantsRooting and hardeningLarge scale cultivationharvestFast dryingMachine trimmingExtractionActive ingredientFormulationFilling and packagingDistribution Processing can remove impurities, so the finished extract is standardised before it is filled. Finished packaged flower (Flos)Mother plantsRooting and hardeningSmall scale cultivationharvestWet hang harvestSlow cool dryingHand trimmingCuringPackagingDistribution Covered end to end by GMP Annex 2. The flower itself is the finished medicine, so nothing can be cleaned out of it

<p>The post Seed To Patient first appeared on PatientsCann UK®.</p>